- Randomized Phase III Study Comparing Preoperative Chemoradiotherapy Alone Versus Neoadjuvant Chemotherapy With Folfirinox Regimen Followed by Preoperative Chemoradiotherapy for Patients With Resectable Locally Advanced Rectal Cancer


Condition: Cancer of the Rectum

Intervention:

  • Drug: mFolfirinox
  • Radiation: Radiotherapy 50Gy
  • Drug: Capecitabine
  • Procedure: TME surgery
  • Drug: mFolfox6 or capecitabine

Purpose: National, multi-center, open-label,randomized, 2-arm phase III superiority trial, comparing neoadjuvant chemotherapy (CT) with mFolfirinox followed by preoperative chemoradiotherapy (CRT), versus preoperative CRT in patients with locally advanced rectal cancer.

Study Type: Interventional

Clinical Trials Identifier NCT 8-digits: NCT01804790

Sponsor: UNICANCER

Primary Outcome Measures:

  • Measure: disease-free survival
  • Time Frame: 3 years
  • Safety Issue:

Secondary Outcome Measures:

  • Measure: Overall survival
  • Time Frame: 7 years
  • Safety Issue:

Estimated Enrollment: 460

Study Start Date: January 2012

Phase: Phase 3

Eligibility:

  • Age: minimum 18 Years maximum 75 Years
  • Gender: All

Inclusion Criteria:

  • Histogically proven rectal adenocarcinoma
  • Stages cT3 with risk of local recurrence or cT4, M0 and for which a multidisciplinary meeting recommend preoperative CRT
  • Resectable tumor, or considered as potentially resectable after CRT
  • No distant metastases
  • Patient eligible for surgery
  • Patient aged from 18 to 75 years
  • WHO/ECOG performance status 0/2.
  • No heart failure or coronary heart disease symptoms (even controlled).
  • No peripheral neuropathy > grade 1
  • No prior radiotherapy of the pelvis for any reason and no previous CT
  • No major comorbidity that may preclude the delivery of treatment and no active infection (HIV or chronic hepatitis B or C).
  • Adequate contraception in fertile patients.
  • Adequate hematologic function
  • Adequate hepatic function
  • Signed written informed consent

Exclusion Criteria:

  • Metastatic disease
  • Unresectable rectal cancer, including prostatic involvement or extension to pelvic floor muscles
  • Contraindication to 5-FU, or to oxaliplatin or to irinotecan, including Gilbert disease or genotype UGT1A1
  • Medical history of chronic diarrhea or inflammatory disease of the colon or rectum
  • Medical history of angina pectoris or myocardial infarction
  • Progressive active infection or any other severe medical condition that could jeopardize treatment administration
  • Other concomitant cancer, or medical history of cancer other than treated in situ cervical carcinoma or basocellular carcinoma or spinocellular carcinoma
  • Patient included in another clinical trial testing an investigational agent.
  • Pregnant or breast-feeding woman.
  • Persons deprived of liberty or under guardianship or incapable of giving consent
  • Any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol or follow-up schedule.

Contact:

  • Trevor Stanbury
  • 33144235567

Locations:

  • Centre hospitalier Universitaire d'Amiens
  • Amiens France
  • ICO - Site Paul Papin
  • Angers France
  • Centre hospitalier d'Auxerre
  • Auxerre France
  • Centre Hospitalier de Beauvais
  • Beauvais France
  • Institut de Cancérologie de Franche Comté
  • Besancon France
  • Centre Hospitalier de Blois
  • Blois France
  • Hopital Avicenne
  • Bobigny France
  • Clinique Tivoli
  • Bordeaux France
  • Hopital Saint Andre
  • Bordeaux France
  • Institut Bergonie
  • Bordeaux France
  • Centre Francois Baclesse
  • Caen France
  • Chd de La Roche Sur Yon - Les Oudairies
  • La Roche-sur-yon France
  • Centre Bourgogne
  • Lille France
  • Centre Oscar Lambret
  • Lille France
  • Centre Léon Bérard
  • Lyon France
  • Hopital Prive Jean Mermoz
  • Lyon France
  • Ap Hm - Hopital de La Timone - Adultes
  • Marseille France
  • Institut de Cancérologie de Franche Comté
  • Montbeliard France
  • Centre Azuréen de cancérologie
  • Mougins France
  • Hopital Emile Muller
  • Mulhouse France
  • centre Alexis Vautrin
  • Nancy France
  • Polyclinique de Gentilly
  • Nancy France
  • Centre Antoine Lacassagne
  • Nice France
  • Groupe Hospitalier La Pitie-Salpetriere
  • Paris France
  • Institut Mutualiste Montsouris
  • Paris France
  • Hopital Haut Leveque
  • Pessac France
  • Centre Hospitalier Regional D'Annecy
  • Pringy France
  • Hopital Robert Debre
  • Reims France
  • Institut Jean Godinot
  • Reims France
  • Clinique Armoricaine de Radiologie
  • Saint-brieuc France
  • Hopital Saint Gregoire
  • Saint-gregoire France
  • Clinique Mutualiste de L'Estuaire
  • Saint-nazaire France
  • Centre Hospitalier de la Réunion - Site du GHSR
  • Saint-pierre France
  • ICO - Site René Gauducheau
  • St Herblain France
  • Centre Paul Strauss
  • Strasbourg France
  • Gustave Roussy
  • Villejuif France

View trial on ClinicalTrials.gov


E-Newsletters

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.

Subscribe